1552P - Evaluation of the quality of life and economic burden with granulocyte-colony stimulating factor in Chinese breast cancer patients receiving docetax...

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Supportive Care
Breast Cancer
Presenter Mengye He
Authors M. He1, S. Huang2, L. Yu3, G. Shi2, J. Deng2, X. Zhang2, X. Wang2, J. Chen2, X. Nong4, P. Shen2
  • 1First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou/CN
  • 2Medical Oncology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou/CN
  • 3Medical Oncology Dept., First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou/CN
  • 4Department Of Medical Oncology, 1st Affiliated Hospital of ZhejiangUniversity School of Medicine, CN-310003 - Hangzhou/CN

Abstract

Background

Docetaxel, Epirubicin, cyclophosphamide (TEC) has been accepted as the standard care in the treatment of Chinese patients with breast cancer. However, little is known about the impact of primary prophylactic granulocyte-colony stimulating factor (G-CSF) on the quality of life(QOL) and economic burden in these patients.

Patients and methods

This was a randomized control study to compare G-CSF as primary prophylactics or not while breast cancer patients receiving TEC chemotherapy. Primary prophylactic G-CSF (PPG) was: filgrastim 3mcg/kg/day on day 3-8 (n = 53 patients); G-CSF for treatment was: filgrastim 5mcg/kg/day on the occasion that grade 3-4 neutropenia, febrile neutropenia, and delayed recovery of absolute neutrophil count on day 21 till the neutrophil recovery (n = 54 patients). A total of 107 patients from single centre in China were included in the trial. Side-effects, costs and the scores of the EORTC QLQ-C30 questionnaires were compared in the two groups.

Results

The addition of PPG to TEC significantly reduced the incidence of neutropenic fever (15.32% vs 6.94%, P = 0.0482), grade 3–4 neutropenia (52.3% vs 12.2%, P < 0.001) and anaemia, asthenia, stomatitis, anorexia, myalgia and dysgeusia. Patient's QOL decreased during chemotherapy, more in TEC without PPG than TEC with PPG, but returned to baseline afterwards. The addition of PPG significantly reduced the percentage of patients with clinically relevant Global Health Status deterioration at the end of treatment (60% versus 47%, P =0.0331). The average cost of each cycle was quite approaching in the two groups (CNY 16432.01 in TEC with PPG vs CNY 16059.24 in TEC without PPG, P > 0.05), but the cost of G-CSF was increased at the end of chemotherapy without PPG.

Conclusions

The addition of PPG significantly reduces the incidence of neutropenic fever as well as that of some TEC-induced haematological and extrahaematological side-effects. The QOL is elevated during chemotherapy by using PPG, particularly in the end of treatment. Economically speaking, primary prophylactic G-CSF is cost-effective in Chinese breast cancer patients receiving TEC chemotherapy.

Disclosure

All authors have declared no conflicts of interest.